This content is intended for healthcare professionals only.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.
Login
Don't have an account yet? Register now
Lost your password? Reset password
OR
Login with DocCheck Login with Linkedin
Access as a guest
Choose Language
English
English
https://beigenemedical.info/search/EHA/
Italian
https://beigenemedical.info/it/search/EHA/
French
https://beigenemedical.info/fr/search/EHA/
Spanish
https://beigenemedical.info/es/search/EHA/
German
https://beigenemedical.info/de/search/EHA/
I am not a Healthcare Professional

Please login or register for full access

Register
Already registered? Login
Skip to content
Choose Language
English
English
English
Italian
Italian
French
French
Spanish
Spanish
German
German
Login / Register
  • Congresses
    • Congress Calendar
    • Virtual Congress
  • BeiGeneius
  • Pipelines
Choose Language
English
English
English
Italian
Italian
French
French
Spanish
Spanish
German
German

EHA

European Hematology Association
All Types
All Types
Reading
reading
Slide-Kit
slidekit
Video
video
Latest
Latest
latest
Oldest
oldest
All Types
All Types
Reading
reading
Slide-Kit
slidekit
Video
video
Latest
Latest
latest
Oldest
oldest
Suggested:
CLL
EHA
ESMO
Hematologic malignancies
Solid tumor
WM
Mazyar Shadman

Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

Abstract presented at EHA2022 describing a study of zanubrutinib in acalabrutinib-intolerant patients
with B-cell malignancies.

Reading
13 May 2022
EHA
Zanubrutinib
BTKi
Please login or register to access the download
Stephen Opat

BCL2 inhibitor BGB-11417 as monotherapy or with zanubrutinib in B-cell malignancies: Preliminary data

Abstract presented at EHA2022 describing preliminary data from a phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies.

Reading
13 May 2022
EHA
BCL2
Zanubrutinib
Please login or register to access the download
Jake Shortt

BGB-11417, a potent and selective BCL2 inhibitor, in acute myeloid leukemia (AML): Preliminary safety and efficacy

Abstract presented at EHA2022 describing preliminary safety and efficacy of BGB-11417, a potent
and selective BCL2 inhibitor, in patients with acute myeloid leukemia (AML).

Reading
13 May 2022
EHA
BCL2
Please login or register to access the download
memo

Memo inHaematology - ASCO, EHA and ICML 2021 congress report

Report on targeted and immune-directed therapies in B-cell malignancies presented at ASCO, EHA and ICML 2021.

Reading
15 Dec 2021
EHA
ASCO
ICML
memo

Memo inHaematology - ASCO, EHA and ICML 2021 congress report

Report on recent developments in the treatment of B-cell malignancies presented at ASCO, EHA and ICML 2021.

Slide-Kit
15 Dec 2021
EHA
ASCO
ICML
Load More

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

As part of scientific exchange, BeiGene is providing the most recent abstract(s) accepted by the referenced scientific congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of BeiGene products.​

  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Legal notice

waldenstroms.info

memo inOncology

© BeiGene 2022. All rights reserved.   |   Cookie Settings

You're now leaving the website beigenemedical.info

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave beigenemedical.info website. The link will take you to another BeiGene website, the content of which is subject to the locally applicable laws and regulations.

BeGene Switzerland GmbH makes no representation that the information provided on the website is suitable or available for use or access in locations outside the country for which the website is intended.

Please ensure that you belong to the target group of the content provided on the linked website and that your access to it complies with the applicable laws and regulations.

No, I want to go back Yes, I would like to continue

You're now leaving the website beigenemedical.info

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave beigenemedical.info website. The link will take you to a website owned and operated by an independent party over which BeiGene Switzerland GmbH has no control or influence (“third-party website”).​

BeiGene Switzerland GmbH makes no representation that information on the third-party website is appropriate or available for use or access in locations outside the country for which the third-party website is intended. Therefore, BeiGene Switzerland GmbH declines any responsibility for third-party information. BeiGene Switzerland GmbH makes no representation regarding the data usage policies of the third party website and declines any responsibility for the use of personal data by the operator of the third-party website. Please ensure that you belong to the intended audience of the content provided on third-party website and that your access to it complies with the applicable laws and regulations.

Do you really want to leave the beigenemedical.info website?

No, I want to go back Yes, I would like to continue